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CORRESPONDENCE
Letters to the Editor
The UNLOAD Trial:
A “Nephrologic” Standpoint
We read with great interest the paper of Costanzo et al. (1) (the
UNLOAD [Ultrafiltration vs. IV Diuretics for Patients Hospital-
ized for Acute Decompensated CHF] trial) recently published in
the Journal. This large-scaled randomized trial evaluated the role of
ultrafiltration in decompensated heart failure (HF) and concluded
on its safety and efficacy. Because extracorporeal ultrafiltration and
peritoneal ultrafiltration are the 2 therapies for HF that originally
were used in the treatment of kidney diseases, nephrologists
frequently are consulted to assist in management of refractory HF.
Although excited about the positive results of this trial, we think a
number of concerns exist that, if addressed in future studies, might
lead to a wider acceptance of this modality.
First, patients with a systolic blood pressure of 90 mm Hg
were excluded from the study. Because patients in the ultrafiltra-
tion group are theoretically at greater risk of hemodynamic
instability secondary to the nature of the therapy, elimination of
the unstable patients can potentially act in favor of ultrafiltration.
Interestingly, even in the hemodynamically stable patients in-
cluded in this study, hypotension was twice more frequent in the
ultrafiltration group. Moreover, the mean furosemide-equivalent
diuretic dose in the whole study population is 124 mg/day, which
is approximately 20% of the maximal recommended dose for
management of HF) (2). This again suggests that the study
population might represent a relatively more stable subset of these
patients and that it potentially might have acted in favor of
ultrafiltration.
Second, this trial cannot provide information on long-term
outcome of patients treated by ultrafiltration. Although some
authors have tried to explore the role of ultrafiltration in removal
of undesirable cytokines (3), its potential impact on eliminating
other essential molecules (e.g., lymphokines) has yet to be clarified.
A follow-up period of 90 days might not be sufficient to determine
the safety of this therapeutic strategy and its potential impact on
long-term morbidity and mortality.
Third, inotrope medications can be used in combination with
diuretics as part of standard care for decompensated HF (4). In the
UNLOAD trial, patients receiving vasopressors or vasoactive
agents have been excluded, making it problematic to extrapolate
the benefits of mechanical ultrafiltration to patients undergoing
different pharmacologic management standards and protocols.
Fourth, the complexity of the practical aspects of extracorporeal
ultrafiltration needs to be considered and reported. These potential
issues include the need for placement of central venous catheters in
a subset of patients; inadequate anticoagulation and other technical
problems leading to premature clotting and thus replacement of
the very costly extracorporeal circuits and hemofilters; and diffi-
culty in a precise assessment of fluid overload, which unfortunately
could lead to inappropriately high ultrafiltration rates and subse-
quent complications including acute renal failure.
Finally, future studies are needed to further investigate the
proposed concept of there being a physiologic (i.e., neurohumoral)
superiority for equivalent fluid removal by extracorporeal modali-
ties as compared with aggressive diuresis. In this regard, certain
other services provided by nephrologists could potentially have an
important role in the care of these patients: Other recently
developed hemofiltration devices and peritoneal ultrafiltration are
alternative outpatient approaches with significantly lower cost that
could lead to more widespread acceptance of this treatment
strategy.
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Reply
The UNLOAD trial investigators appreciate the opportunity to
reply to Dr. Kazory and colleagues. In response to their assertions,
UNLOAD’s subjects reflect “real-world” patients hospitalized
with heart failure (HF) patients, 90% of whom have congestion
with normal cardiac output and blood pressure (1). UNLOAD’s
subjects had advanced HF (mean New York Heart Association
[NYHA] functional class  3.4, Minnesota Living with Heart
Failure scores  70, BNP levels 1,200 pg/ml, 1.5 HF hospital-
izations in 12 months). In addition, hypotensive episodes were
similar in the 2 groups throughout the follow-up period (p 
0.113) (2).
During hospitalization, 43% of standard care patients lost 4.5
kg, weight loss exceeding that of two-thirds of ADHERE (Acute
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Decompensated Heart Failure National Registry) subjects. Guide-
lines caution against the use of high diuretic doses, which can
worsen hypotension and renal insufficiency (3). Loop diuretic
therapy has been associated with increased morbidity and mortality
attributable to deleterious effects on neurohormonal activation,
electrolyte balance, and cardiorenal function (4). According to the
nephrologic literature: 1) in severe renal insufficiency, maximal
natriuretic response occurs with intravenous furosemide doses of
160 to 200 mg; 2) the natriuretic response to maximal loop diuretic
doses in NYHA functional class II to IV patients with HF is
one-third of that in normal subjects; and 3) in patients with HF,
diuretic response is enhanced by giving moderate diuretic doses
more frequently, not by giving larger doses (4). Second, the
UNLOAD trial was not designed to detect mortality differences;
the UNLOAD trial was powered to detect differences in HF
rehospitalizations, which, at 90 days, were 50% fewer in the
ultrafiltration group. To date, ultrafiltration is the only therapy for
decompensated HF shown to have both immediate and sustained
benefit. Third, because inotropes increase morbidity and mortality,
their use was restricted to patients with poor perfusion (3). Finally,
early filter replacement was required in 2 patients because of filter
clotting. In the UNLOAD trial, because of either patient selection
and/or the use of the Aquadex System guided by cardiologists,
mechanical fluid removal was not associated with the complica-
tions observed in patients with end-stage renal disease (ESRD)
undergoing repeated extracorporeal ultrafiltration. Therapy-related
complications should be weighted against the harm of recurrent
HF decompensation on both the heart and the kidney.
Tools to determine optimal blood volume in individual patients
are critically needed to establish optimal ultrafiltration rates. The
mechanisms linking different methods of fluid removal to clinical
benefit deserve further investigation. Notably, despite similar fluid
loss by ultrafiltration and continuous intravenous diuretics, sus-
tained benefit, as indicated by fewer HF rehospitalizations, oc-
curred only with ultrafiltration. Thus, removal of isotonic ultrafil-
trate versus hypotonic urine may be a superior strategy for volume
overloaded patients with HF (2). That alternative mechanical
fluid-removal services provided by nephrologists might be valuable
in volume-overloaded HF patients without renal failure is an
interesting and testable hypothesis. The U.S. Renal Data System
documents that HF morbidity in patients with ESRD exceeds that
of NYHA functional class IV HF patients. Because, by themselves,
current fluid-management strategies in ESRD patients may inad-
equately address cardiorenal interactions, services provided by HF
specialists may improve the care of ESRD patients.
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